肺动脉高压治疗进展

Updates in treatment of pulmonary arterial hypertension

动脉型肺动脉高压(PAH)是临床上的治疗难题,近年来,随着对PAH发病机制认识的深入,开发了一系列针对肺动脉高压不同发病机制的特异性药物。肺动脉高压的常规治疗包括氧疗、抗凝、利尿治疗等,钙通道阻滞剂仅应用于急性血管反应试验阳性的患者,且其药物剂量要足够大。特异性血管扩张药物包括前列环素类似物、内皮素受体拮抗剂和磷酸二酯酶抑制剂等,随着特异性血管扩张剂的开发与应用,肺动脉高压患者的预后已明显改观。

Pulmonary arterial hypertension（PAH）remains clinically a difficult problem for therapeutics.With the recent remarkable progress in the pathogenic mechanisms of this disease,a series of specific drugs targeting different pathogenic mechanisms of PAH have been developed.The conventional therapy of PAH includes oxygen therapy,anticoagulants and diuretics.Calcium channel antagonists are indicated only for certain PAH patients who are positive in acute vascular reaction test,and should be used with adequately higher doses.Along with development and introduction of specific vasodilators,such as prostacyclin analogues,endothelin receptor antagonists and phosphodiesterase inhibition,outcomes of PAH has been substantially improved.